A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Trial Profile

A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Amlodipine/candesartan-cilexetil (Primary) ; Amlodipine; Candesartan cilexetil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Shin Poong Pharmaceutical
  • Most Recent Events

    • 19 Jul 2017 Primary endpoint (Change in mean sitting Diastolic Blood Pressure (msDBP) at week 8 compared to baseline-CAN/AML (8 mg/10 mg) versus CAN (8 mg) monotherapy) has been met, according to results published in the Clinical Therapeutics Journal.
    • 19 Jul 2017 Primary endpoint (Change in mean sitting Diastolic Blood Pressure (msDBP) at week 8 compared to baseline-CAN/AML (8 mg/5 mg, 16 mg/5 mg, and 16 mg/10 mg) versus CAN (8 mg, 16 mg) or AML (5 mg, 10 mg) monotherapy) has been met, according to results published in the Clinical Therapeutics Journal.
    • 19 Jul 2017 Results published in the Clinical Therapeutics Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top